Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;81(4):390-401.
doi: 10.1002/ddr.21636. Epub 2020 Jan 9.

A review of phenformin, metformin, and imeglimin

Raghunandan Yendapally  1 , Donald Sikazwe  1 , Subin S Kim  1 , Sushma Ramsinghani  1 , Rheaclare Fraser-Spears  1 , Amy P Witte  1 , Brittany La-Viola  2
Affiliations
Review

A review of phenformin, metformin, and imeglimin

Raghunandan Yendapally et al. Drug Dev Res. 2020 Jun.

Abstract

Diabetes mellitus is a serious metabolic disorder affecting millions of people worldwide. Phenformin and metformin are biguanide antidiabetic agents that are conveniently synthesized in a single-step chemical reaction. Phenformin was once used to lower blood glucose levels, but later withdrawn from the market in several countries because it was frequently associated with lactic acidosis. Metformin is still a widely prescribed medication for the treatment of type 2 diabetes despite the introduction of several newer antidiabetic agents. Metformin is administered orally and has desirable pharmacokinetics. Incidence of metformin-induced lactic acidosis is serious but very rare. Imeglimin, a novel molecule being investigated by Poxel and Sumitomo Dainippon Pharma in Japan, is currently in clinical trials for the treatment of type 2 diabetes. Unlike metformin, imeglimin is a cyclic molecule containing a triazine ring. However, like metformin, imeglimin is also a basic small molecule. Imeglimin is synthesized from metformin as a precursor via a single step chemical reaction. Recent mechanism of action studies suggests that imeglimin improves mitochondria function, when given in combination with metformin it helps achieve better glycemic control in patients with type 2 diabetes. We herein describe and compare the current status, synthesis, physicochemical properties, pharmacokinetic parameters, mechanism of action, and preclinical/clinical studies of metformin and imeglimin.

Keywords: diabetes; imeglimin; metformin; pharmacokinetics; phenformin; physicochemical properties; therapeutics.

PubMed Disclaimer

References

REFERENCES

    1. Abdul-Ghani, M., & DeFronzo, R. A. (2017). Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care, 40(8), 1121-1127. https://doi.org/10.2337/dc16-2368
    1. ADA. (2010). American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 1(Suppl. 1), S62-S69. https://doi.org/10.2337/dc10-S062
    1. ADA. (2019). American Diabetes Association, pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019. Diabetes Care, 42(Suppl. 1), S90-S102. https://doi.org/10.2337/dc19-S009
    1. Alkalay, D., Khemani, L., Wagner, W. E., & Bartlett, M. F. (1975). Pharmacokinetics of phenformin in man. Journal of Clinical Pharmacology, 15(5-6), 446-448. https://doi.org/10.1002/j.1552-4604.1975.tb02367.x
    1. Al-Khalili, L., Forsgren, M., Kannisto, K., Zierath, J. R., Lonnqvist, F., & Krook, A. (2005). Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia, 48(6), 1173-1179. https://doi.org/10.1007/s00125-005-1741-3

MeSH terms

LinkOut - more resources